title: Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
abstract: To examine the efficacy and toxicity of oral 3,4 diaminopyridine (DAP) in dosages up to 100 mg/day, 36 patients with multiple sclerosis (MS) enrolled in a randomized, double-blind, placebo-controlled, crossover trial. The primary outcome measure was improvement of a prospectively defined neurologic deficit, which was leg weakness in 34 patients. Secondary outcome measures included the patient's subjective response, scored manual motor testing (MMT) of leg strength, scored leg strength from videotaped motor testing (VMT), quadriceps and hamstrings strength (QMT) measured by isometric dynamometry, neuropsychological testing (NPT), ambulation index (AI), and Expanded Disability Status Scale (EDSS) score. Paresthesias and abdominal pain were common and were dose limiting in eight patients. Three patients had episodes of confusion, and one patient had a seizure while on DAP. Eight patients withdrew from the study, leaving 28 evaluable patients for the efficacy analysis. The prospectively defined neurologic deficit improved in 24 patients-22 on DAP and 2 on placebo (p = 0.0005). All improvements were in leg weakness. Subjective response and measures of leg strength and function (MMT, VMT, QMT, and AI) improved on DAP compared with placebo. Neither NPT nor EDSS scores improved. DAP treatment can induce improvements in leg strength in MS patients, but toxicity is limiting in many patients.
authors.affiliation: Department of Neurology, School of Medicine, University of Maryland, Baltimore, USA.
authors.forename: C T
authors.initials: CT
authors.lastname: Bever
authors.forename: P A
authors.initials: PA
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Leslie
authors.forename: H S
authors.initials: HS
authors.lastname: Panitch
authors.forename: S
authors.initials: S
authors.lastname: Dhib-Jalbut
authors.forename: O A
authors.initials: OA
authors.lastname: Khan
authors.forename: R
authors.initials: R
authors.lastname: Milo
authors.forename: J R
authors.initials: JR
authors.lastname: Hebel
authors.forename: K L
authors.initials: KL
authors.lastname: Conway
authors.forename: E
authors.initials: E
authors.lastname: Katz
authors.forename: K P
authors.initials: KP
authors.lastname: Johnson
mesh_terms: D015761:4-Aminopyridine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000077770:Amifampridine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007866:Leg / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D015761:4-Aminopyridine; D000077770:Amifampridine